Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Oncology and Therapy|May 15, 2021
A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination TherapyChin-Chou Wang, Li-Chung Chiu, Pi-Hung Tung, et al.
Journal of Cellular and Molecular Medicine|March 26, 2018
Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine modelPing-Chih Hsu, Jinbai Miao, Zhen Huang, et al.
International Journal of Oncology|June 1, 2017
DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesotheliomaHui Wang, Yu-Yuan Dai, Wen-Qian Zhang, et al.
Immunity, Inflammation and Disease|November 25, 2020
Impaired interferon-α expression in plasmacytoid dendritic cells in asthmaTing-Yu Lin, Chun-Yu Lo, Kuo-Chien Tsao, et al.
American Journal of Cancer Research|September 11, 2023
Clinical outcome analysis of non-small cell lung cancer patients with brain metastasis receiving metastatic brain tumor resection surgery: a multicenter observational studyPing-Chih Hsu, Li-Chung Chiu, Ko-Ting Chen, et al.
Chemotherapy|April 15, 2015
Overall response to first-line tyrosine kinase inhibitor and second-line chemotherapy is predictive of survival outcome in epidermal growth factor receptor-mutated adenocarcinomaScott Chih-Hsi Kuo, Ping-Chih Hsu, Chih-Hung Chen, et al.
Therapeutic Advances in Medical Oncology|June 29, 2026
Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysisPing-Chih Hsu, How-Wen Ko, Li-Chung Chiu, et al.
Pharmaceuticals (Basel, Switzerland)|October 29, 2020
The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational StudyPing-Chih Hsu, Chun-Yao Huang, Chin-Chou Wang, et al.
Journal of Cellular and Molecular Medicine|May 5, 2017
Targeting YAP in malignant pleural mesotheliomaWen-Qian Zhang, Yu-Yuan Dai, Ping-Chih Hsu, et al.
Oncotarget|December 13, 2017
The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutationsChien-Ying Liu, Chih-Liang Wang, Shih-Hong Li, et al.
Pageof 8